Upadacitinib Mechanism of Action: How Upadacitinib Works | Elicit
Upadacitinib Mechanism of Action
How Upadacitinib (Rinvoq) Works: JAK inhibition of cytokine-induced STAT phosphorylation (JAK1/JAK3).
Last updated:
March 2026
Quick Summary
Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor used in immune-mediated inflammatory diseases, including ulcerative colitis and Crohn disease. In human leukocyte cellular assays, it inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3, helping reduce inflammatory signaling. Phase 3 trials demonstrated efficacy in achieving clinical remission and endoscopic response in inflammatory bowel disease.
Properties
- Generic Name: Upadacitinib
- Brand Names: Rinvoq
- Drug Class: Janus kinase (JAK) inhibitor
- Primary Target: Janus kinase 1 (JAK1) / Janus kinase 3 (JAK3)
- Approved Indications: Moderate-to-severe rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS) / radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, moderate-to-severe atopic dermatitis (adults and adolescents ≥12 years), moderately to severely active Crohn's disease, moderately to severely active ulcerative colitis
- Key Effect: Inhibits cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3
Development History
Upadacitinib (development code ABT-494) was engineered by AbbVie and emerged from a structure-based medicinal chemistry program targeting the imidazopyrrolopyridine scaffold. The central design objective was to achieve meaningful JAK1 selectivity over JAK2, JAK3, and TYK2, addressing the principal liability of first-generation JAK inhibitors: hematopoietic adverse effects (anemia, neutropenia) attributed predominantly to JAK2 co-inhibition.
The pivotal approval program for upadacitinib in rheumatoid arthritis comprised six phase 3 trials under the SELECT umbrella, enrolling approximately 4,400 patients. Upadacitinib 15 mg once daily achieved all primary and ranked secondary endpoints across all five pivotal trials.
Detailed Mechanism of Action
Absorption and distribution. Upadacitinib is an orally administered small-molecule JAK inhibitor whose systemic exposure is shaped primarily by CYP3A4-mediated metabolism. Co-administration with strong CYP3A4 inhibitors or inducers can significantly affect exposure.
ATP-competitive JAK1 engagement. Upadacitinib reaches immune-relevant compartments and engages JAK family kinases at their conserved ATP-binding site, functioning as competitive inhibitors of ATP.
Interruption of JAK–STAT signalling. Occupation of the JAK1 ATP site prevents the autophosphorylation and transphosphorylation events required for STAT activation. Pharmacodynamic studies demonstrate selective inhibition of JAK1-mediated signaling pathways.
Clinical translation. Exposure–response modelling informed Phase III dose selection for both rheumatoid arthritis and ulcerative colitis indicating an alignment between mechanistic properties and clinical outcomes.
Clinical Relevance
Approved Indications
Rheumatoid Arthritis: Adults with moderately to severely active RA after inadequate response or intolerance to methotrexate.
Psoriatic Arthritis: Adults and pediatric patients ≥2 years with active PsA after inadequate response or intolerance to TNF blockers.
Atopic Dermatitis: Adults and adolescents with moderate-to-severe AD not adequately controlled with systemic therapy.
Ankylosing Spondylitis: Adults with active AS after inadequate response or intolerance to TNF blockers.
Ulcerative Colitis & Crohn's Disease: Indicated for adults with moderately to severely active diseases after inadequate response or intolerance to TNF blockers.
Key Drug Interactions (Mechanism-Based)
- Strong CYP3A4 Inhibitors: Increase upadacitinib exposure; dose adjustment required.
- Strong CYP3A4 Inducers: Decrease upadacitinib exposure; not recommended with concurrent use.
Black Box Warnings
- Serious Infections: Risk of serious infections including tuberculosis.
- Increased Mortality & Malignancy: Observed with another JAK inhibitor compared to TNF blockers.
Emerging Indications
Immunology
- Systemic Lupus Erythematosus: Phase 2 trials showing promising efficacy in inhibiting innate/adaptive immune activation.
- Hidradenitis Suppurativa: Indications for ongoing trials assessing efficacy.
Clinical Trials of Upadacitinib
| Trial Name | Phase | N Enrolled | Indication | Key Result | Status |
|---|---|---|---|---|---|
| SELECT-GCA | Phase 3 | 428 | Giant-Cell Arteritis | 46% remission compared to 29% with placebo. | Ongoing |
| AD Up | Phase 3 | 901 | Atopic Dermatitis | 81.5% EASI 75 response at week 140. | Ongoing |
| SELECT-COMPARE | Phase 3 | 1629 | Rheumatoid Arthritis | 31.8% achieved clinical remission at week 264. | Ongoing |
Upadacitinib Competitive Landscape
This table shows how Upadacitinib compares to other JAK inhibitors for immune-mediated inflammatory diseases:
| Drug Class | Representative Drug(s) | Mechanism of Action |
|---|---|---|
| JAK inhibitors | Tofacitinib, Upadacitinib | Block the JAK-STAT signaling pathway, reducing inflammatory gene expression. |
| IL-6 receptor inhibitors | Tocilizumab | Monoclonal antibodies that inhibit IL-6, affecting pro-inflammatory signaling. |
| T-cell costimulation modulators | Abatacept | Inhibits T-cell activation by blocking CD80/CD86-CD28 signaling pathway. |
Open Research Questions
- Is JAK1 selectivity sufficient to decouple upadacitinib from cardiovascular risks associated with other JAK inhibitors?
- What is the reproductive safety profile of upadacitinib during pregnancy and lactation?
- How can dosing be optimized for patients in sustained remission?
- What biomarkers predict response to upadacitinib?